Compare ANTA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANTA | ACOG |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | Singapore | Canada |
| Employees | 113 | 71 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.1M | 185.1M |
| IPO Year | N/A | N/A |
| Metric | ANTA | ACOG |
|---|---|---|
| Price | $3.64 | $7.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.17 | $16.00 |
| AVG Volume (30 Days) | 3.3K | ★ 92.2K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.95 | $139.22 |
| Revenue Next Year | $30.46 | $134.48 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $4.50 |
| 52 Week High | $13.82 | $10.14 |
| Indicator | ANTA | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 21.54 | 56.70 |
| Support Level | N/A | $5.27 |
| Resistance Level | $9.81 | $8.80 |
| Average True Range (ATR) | 0.39 | 0.56 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 10.73 | 40.74 |
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.